CA2466863A1 - Oral pharmaceutical compositions comprising cromolyn sodium and an acylated amino acid - Google Patents

Oral pharmaceutical compositions comprising cromolyn sodium and an acylated amino acid Download PDF

Info

Publication number
CA2466863A1
CA2466863A1 CA002466863A CA2466863A CA2466863A1 CA 2466863 A1 CA2466863 A1 CA 2466863A1 CA 002466863 A CA002466863 A CA 002466863A CA 2466863 A CA2466863 A CA 2466863A CA 2466863 A1 CA2466863 A1 CA 2466863A1
Authority
CA
Canada
Prior art keywords
cromolyn
cromolyn sodium
dosage form
delivery agent
sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002466863A
Other languages
English (en)
French (fr)
Inventor
Richat Abbas
Ehud Arbit
Michael Goldberg
Vivian Wong
Donald J. Sarubbi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emisphere Technologies Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2466863A1 publication Critical patent/CA2466863A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA002466863A 2001-11-29 2002-11-29 Oral pharmaceutical compositions comprising cromolyn sodium and an acylated amino acid Abandoned CA2466863A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US33439501P 2001-11-29 2001-11-29
US60/334,395 2001-11-29
US38491602P 2002-05-24 2002-05-24
US60/384,916 2002-05-24
PCT/US2002/038247 WO2003045331A2 (en) 2001-11-29 2002-11-29 Formulations for oral administration of cromolyn sodium

Publications (1)

Publication Number Publication Date
CA2466863A1 true CA2466863A1 (en) 2003-06-05

Family

ID=26989179

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002466863A Abandoned CA2466863A1 (en) 2001-11-29 2002-11-29 Oral pharmaceutical compositions comprising cromolyn sodium and an acylated amino acid

Country Status (6)

Country Link
US (2) US20040259952A1 (enExample)
EP (1) EP1461031B1 (enExample)
JP (1) JP5196701B2 (enExample)
AU (1) AU2002352974A1 (enExample)
CA (1) CA2466863A1 (enExample)
WO (1) WO2003045331A2 (enExample)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050209141A1 (en) * 2003-10-17 2005-09-22 Silver Randi B Mast cell-derived renin
US7217703B2 (en) 2004-04-16 2007-05-15 Emisphere Technologies, Inc. 8-(2-hydroxyphenoxy)octyldiethanolamine and salts thereof for delivery of active agents
EP1756039B1 (en) 2004-05-14 2012-10-17 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
NZ588373A (en) 2004-05-19 2012-01-12 Emisphere Tech Inc Topical cromolyn formulations
AU2005244985B2 (en) 2004-05-19 2011-09-01 Emisphere Technologies, Inc. Acyclovir formulations
NZ556373A (en) 2004-12-29 2010-01-29 Emisphere Tech Inc Pharmaceutical formulations of gallium salts
US8110547B2 (en) 2005-01-12 2012-02-07 Emisphere Technologies, Inc. Compositions for buccal delivery of parathyroid hormone
WO2007052398A1 (ja) * 2005-11-01 2007-05-10 Reverse Proteomics Research Institute Co., Ltd. アレルギー疾患の治療に有用な化合物をスクリーニングする方法
GB0522566D0 (en) * 2005-11-04 2005-12-14 Novartis Ag Organic compounds
US20070249727A1 (en) 2006-04-21 2007-10-25 The Proctor & Gamble Company Compositions and kits useful for treatment of respiratory illness
US10022339B2 (en) 2006-04-21 2018-07-17 The Procter & Gamble Company Compositions and methods useful for treatment of respiratory illness
CA2656019C (en) 2006-06-28 2016-09-13 Emisphere Technologies, Inc. Gallium nitrate formulations
US8445437B2 (en) * 2006-07-27 2013-05-21 The Brigham And Women's Hospital, Inc. Treatment and prevention of cardiovascular disease using mast cell stabilizers
JP5460600B2 (ja) * 2007-09-28 2014-04-02 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 肥満症治療における肥満細胞安定化薬
US10517839B2 (en) * 2008-06-09 2019-12-31 Cornell University Mast cell inhibition in diseases of the retina and vitreous
EP2391618B1 (en) * 2009-01-29 2019-04-03 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
JP5985985B2 (ja) * 2009-08-03 2016-09-06 エミスフィアー テクノロジーズ インコーポレイテッドＥｍｉｓｐｈｅｒｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ，Ｉｎｃ． 胃腸への影響が減少した即効型ナプロキセン組成物
US20110142889A1 (en) * 2009-12-16 2011-06-16 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
RS56998B1 (sr) 2010-12-16 2018-05-31 Novo Nordisk As Čvrste kompozicije koje sadrže agonist glp-1 i so n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline
EP2696687B1 (en) 2011-04-12 2016-10-26 Novo Nordisk A/S Double-acylated glp-1 derivatives
US8843456B2 (en) 2011-12-06 2014-09-23 International Business Machines Corporation Database table compression
CN104203266B (zh) 2012-03-22 2017-12-26 诺和诺德股份有限公司 Glp‑1肽组合物及其制备
DK2827845T3 (en) 2012-03-22 2019-04-01 Novo Nordisk As COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF
ES2965469T3 (es) 2012-03-22 2024-04-15 Novo Nordisk As Composiciones que comprenden un agente de suministro y preparación de estas
CN104487056A (zh) 2012-06-20 2015-04-01 诺和诺德A/S（股份有限公司） 包含肽和递送剂的片剂制剂
US10058530B2 (en) 2012-10-25 2018-08-28 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
JP6499077B2 (ja) 2012-10-25 2019-04-10 ザ ジェネラル ホスピタル コーポレイション アルツハイマー病と関連疾患の治療のための併用療法
EP2978441A4 (en) * 2013-03-27 2017-02-08 ScPharmaceuticals Inc. Combination therapy for subcutaneous administration of glycopeptide antibiotics
BR112015026325A2 (pt) 2013-05-02 2017-07-25 Novo Nordisk As dosagem oral de compostos glp-1
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
CA2928028A1 (en) 2013-10-22 2015-04-30 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
EP3068375B1 (en) * 2013-11-11 2020-04-22 Harish, Ziv Formulations and methods for prevention and treatment of oral allergy syndrome
US9962363B2 (en) 2014-02-10 2018-05-08 Patara Pharma, LLC Mast cell stabilizers treatment for systemic disorders
CA2938996A1 (en) 2014-02-10 2015-08-13 Patara Pharma, LLC Methods for the treatment of lung diseases with mast cell stabilizers
US10583177B2 (en) 2015-02-09 2020-03-10 Entera Bio Ltd. Formulations for oral administration of active agents
WO2017027402A1 (en) 2015-08-07 2017-02-16 Patara Pharma, LLC Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
US10238625B2 (en) 2015-08-07 2019-03-26 Respivant Sciences Gmbh Methods for the treatment of mast cell related disorders with mast cell stabilizers
MX382853B (es) 2016-04-22 2025-03-13 Spoke Sciences Inc Compuestos medicinales y suplementos nutricionales de base vegetal de rápida acción.
CN116850132A (zh) 2016-08-17 2023-10-10 安提拉生物有限公司 用于口服的活性剂的制剂
CN116889562A (zh) 2016-08-31 2023-10-17 通用医疗公司 与神经退行性疾病相关的神经炎症中的巨噬细胞/小胶质细胞
EP3506893A4 (en) * 2016-08-31 2020-01-22 Respivant Sciences GmbH CROMOLYN COMPOSITIONS FOR THE TREATMENT OF CHRONIC COUGH DUE TO IDIOPATHIC PULMONAL FIBROSIS
AU2017339366A1 (en) 2016-10-07 2019-04-11 Respivant Sciences Gmbh Cromolyn compositions for treatment of pulmonary fibrosis
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
MX2019007968A (es) * 2017-01-03 2019-12-05 Receptor Holdings Inc Compuestos medicinales y suplementos nutricionales.
AU2017423862A1 (en) 2017-07-20 2020-02-06 Aztherapies, Inc. Powdered formulations of cromolyn sodium and ibuprofen
CA3084593A1 (en) * 2017-12-04 2019-06-13 The General Hospital Corporation Cromolyn compositions and methods thereof
WO2019149880A1 (en) 2018-02-02 2019-08-08 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
EP3817739A4 (en) 2018-07-02 2022-04-13 The General Hospital Corporation POWDERED FORMULATIONS OF CROMOLYN SODIUM AND ALPHA-LACTOSE
UA122811C2 (uk) * 2018-08-10 2021-01-06 Наталія Миколаївна Тихонівська Фармацевтична композиція
WO2020097686A1 (en) * 2018-11-14 2020-05-22 Holman Pharmaceuticals Pty Ltd Compositions and uses thereof
AU2019385420A1 (en) 2018-11-19 2021-07-08 Spoke Sciences, Inc. N-acylated fatty amino acids to reduce absorption variability in cannabinoid based compositions
KR20210113610A (ko) 2018-12-10 2021-09-16 더 제너럴 하스피탈 코포레이션 크로몰린 에스테르 및 이의 용도
US12458622B2 (en) 2020-04-06 2025-11-04 The General Hospital Corporation Methods of treatment of coronavirus-induced inflammation conditions
US11986492B2 (en) * 2022-09-21 2024-05-21 Ashley Wolchina Allison Oral supplement for preventing colic in horses
CN116509836A (zh) * 2023-03-23 2023-08-01 中山万汉制药有限公司 色甘酸钠－季铵盐复合物及其制备方法与用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6281380A (ja) * 1985-10-04 1987-04-14 Kyoto Yakuhin Kogyo Kk クロモグリク酸誘導体、その製造法および抗アレルギ−剤
US5629020A (en) 1994-04-22 1997-05-13 Emisphere Technologies, Inc. Modified amino acids for drug delivery
US5447728A (en) 1992-06-15 1995-09-05 Emisphere Technologies, Inc. Desferrioxamine oral delivery system
JPH06281380A (ja) 1993-03-26 1994-10-07 Hisaka Works Ltd プレート式熱交換器用ガスケット
US5643957A (en) * 1993-04-22 1997-07-01 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
JP4361601B2 (ja) 1993-04-22 2009-11-11 エミスフェアー・テクノロジーズ・インク 経口薬剤移送組成物およびその方法
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
JP3124041B2 (ja) * 1996-08-30 2001-01-15 京都薬品工業株式会社 アレルギー性皮膚炎治療剤
EP0993831B1 (en) 1997-02-07 2008-01-09 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5888529A (en) * 1997-03-28 1999-03-30 The Regents Of The University Of California Ileus treatment method
US5863944A (en) * 1997-04-30 1999-01-26 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5952353A (en) * 1997-09-19 1999-09-14 Auburn University Treating/preventing heart failure via inhibition of mast cell degranulation
US6287594B1 (en) * 1998-01-20 2001-09-11 Edward S. Wilson Oral liquid compositions
ES2242412T3 (es) * 1998-07-27 2005-11-01 Emisphere Technologies, Inc. Compuestos que permiten administrar agentes activos y composiciones a base de estos compuestos.
CN1313439C (zh) * 1998-08-07 2007-05-02 艾米斯菲尔技术有限公司 用于送递活性剂的化合物和组合物
GB9824604D0 (en) * 1998-11-11 1999-01-06 Hewlett Healthcare Limited Treatment of allergic conditions
AU3378100A (en) * 1999-02-26 2000-09-14 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
IL145546A0 (en) 1999-04-05 2002-06-30 Emisphere Tech Inc Disodium salts, monohydrates, and ethanol solvates for delivering active agents
CA2388240C (en) * 1999-11-05 2010-04-20 Emisphere Technologies, Inc. Phenoxy carboxylic acid compounds and compositions for delivering active agents
WO2001044199A1 (en) * 1999-12-16 2001-06-21 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
CA2292902C (en) * 1999-12-24 2012-12-18 Alain Cadieux Use of calcitonin gene-related peptide in the prevention and alleviation of asthma and related bronchospastic pulmonary diseases
JP4879433B2 (ja) * 2000-01-13 2012-02-22 エミスフェアー・テクノロジーズ・インク 活性剤を送達するための化合物および組成物
US6225356B1 (en) * 2000-01-20 2001-05-01 Jones, Iii Tudor Cromolyn sodium containing composition and method of treatment for vilvar vestibulitis interstitial cystitis vukvar vaginitis and vaginitis dynea
AU2001245273A1 (en) * 2000-02-15 2001-08-27 Board Of Trustees Of The University Of Arkansas Recombinant vector expressing a beta2-adrenergic receptor and use in treating airway and vascular diseases
JP2004521857A (ja) * 2000-06-29 2004-07-22 エミスフェアー・テクノロジーズ・インク 活性剤の送達のための化合物及び組成物
ATE429416T1 (de) * 2000-09-06 2009-05-15 Emisphere Tech Inc Cyanophenoxy-carbonsäuren und zusammensetzungen für die freisetzung aktiver substanzen

Also Published As

Publication number Publication date
US20040259952A1 (en) 2004-12-23
US20080194676A1 (en) 2008-08-14
EP1461031B1 (en) 2016-06-29
JP5196701B2 (ja) 2013-05-15
EP1461031A4 (en) 2011-06-22
AU2002352974A1 (en) 2003-06-10
WO2003045331A3 (en) 2003-08-14
JP2005510535A (ja) 2005-04-21
EP1461031A2 (en) 2004-09-29
AU2002352974A8 (en) 2003-06-10
WO2003045331A2 (en) 2003-06-05
US8513300B2 (en) 2013-08-20

Similar Documents

Publication Publication Date Title
US8513300B2 (en) Formulations for oral administration of cromolyn sodium
ES2234487T3 (es) Sistema de administracion oral de desferrioxamina.
US8426368B2 (en) Method of ameliorating oxidative stress and supplementing the diet
US9907787B2 (en) Method of supplementing the diet and ameliorating oxidative stress
ES2380622T5 (es) Compuestos de anfetamina resistentes al abuso
US5811127A (en) Desferrioxamine oral delivery system
EP2046727B1 (en) Positively charged water-soluble prodrugs of diclofenac with very fast skin penetration rate
US11654198B2 (en) Application of combination of polyethylene glycol and local anesthetic in non-narcotic analgesia
AU706027B2 (en) Pharmaceutical composition for oral administration of flavonoids
CN110354270B (zh) 一种青蒿琥酯聚乙二醇衍生物及其制备方法和应用
US11213484B2 (en) Dipivefrin orally disintegrating tablet formulations
US20040229939A1 (en) Tetrahydrocannabinol compositions and methods of manufacture and use thereof
ES2791775B2 (es) Formulaciones de epinefrina intranasal y metodos para el tratamiento de enfermedades
AU2016219617B2 (en) Positively charged water-soluble prodrugs of aspirin
ES2371462T3 (es) Conjugados de carbohidratos para prevenir el abuso de sustancias controladas.
JPH06500537A (ja) アテローム硬化症の治療のためのアリールヒドロキシ尿素化合物の使用
EP1121931A1 (en) Controlled release oral preparations of esculetin and its derivatives
US11590232B2 (en) Bioconjugates of neuropeptides derivatives
Dehghan et al. Nasal absorption of drugs–barriers and solutions
CA3220246A1 (en) Compositions and methods for treating respiratory distress
CN119925347A (zh) 化合物Pladienolide B作为抗蓖麻毒素保护剂的医药用途
TR201508678A2 (tr) Farmasöti̇k bi̇leşi̇mler
TR201508674A2 (tr) Farmasöti̇k bi̇leşi̇mler

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20180411